{"id":5949,"date":"2025-06-09T16:20:56","date_gmt":"2025-06-09T15:20:56","guid":{"rendered":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/?page_id=5949"},"modified":"2026-03-24T17:12:08","modified_gmt":"2026-03-24T16:12:08","slug":"business-profile","status":"publish","type":"page","link":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/","title":{"rendered":"Business Profile"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Business Profile<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tGo back to Investor Relations<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tIndustry<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tCompany Overview<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tBusiness profile and strategic goals<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Industry<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

320 000<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Number of Veterinarians in the EU and USA<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

28 bln USD<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Global expenditure on Companion Animal Healthcare in 2025<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

14 bln USD<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Veterinary biologics market in 2025<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bioceltix operates in the companion animal healthcare market which is currently enjoying a growth phase, thanks to favourable social trends. According to estimates from market research firms, the market is expected to grow at an average annual rate of 6\u20137% between 2025 and 2035, surpassing 25 bln USD in value by 2035. [1]<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t
Read more <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The anti-inflammatory drug segment, which Bioceltix\u2019s medicinal products target, accounts for approximately 20% of the overall market.<\/p>

A significant factor driving market growth is an ongoing social trend in which pets are increasingly treated as family members. This translates into a steady rise in spending on companion animal healthcare and a growing demand for new, improved therapies\u2014regardless of cost. Another important factor for our business is an increase in the average lifespan of pets, thanks to advances in veterinary diagnostics. As a result, statistically more animals are suffering from locomotor system disorders, similar to how the risk of rheumatoid arthritis increases with age in humans.<\/p>

The products developed by Bioceltix will fall into the category of veterinary biological drugs. This is a new and emerging segment of veterinary medicine, initiated in 2016 with the launch of the world\u2019s first monoclonal antibody for the treatment of atopic dermatitis in dogs. Currently, only a handful of veterinary biologics are available on the market; however, there is growing interest in such products from major industry players. This is mainly due to the therapeutic benefits that biologics offer, as well as strong demand from pet owners seeking the best possible treatment options for their animals.<\/p>

[1] https:\/\/www.futuremarketinsights.com\/reports\/veterinary-biologics-market<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Company Overview<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bioceltix S.A. operates in the field of veterinary medicine. We develop veterinary medicinal candidate products based on the immunomodulatory properties of mesenchymal stem cells used as the active pharmaceutical ingredient. Our future products are intended for the treatment of companion animals. We conduct R&D activities aimed at enabling the clinical trials and full regulatory approval of these drugs by the European Medicines Agency (EMA), following procedures similar to those applied for human medicines. All three of our core products have successfully completed clinical trials. For two of these (BCX-CM-J for osteoarthritis in dogs and BCX-EM for arthritis in horses), we are currently engaged in constructive dialogue with the European market regulator.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Company Profile<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bioceltix\u2019s business model is based on the future sale of rights to its developed medicinal products to industry partners, as well as on manufacturing those products in its own GMP-compliant facility.<\/p>

Product rights may be sold through partnership, licensing, or distribution agreements. Our intention is for the developed medicines to be distributed by major industry partners with established international sales networks.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t
Read more <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We plan to generate revenue primarily through in-house manufacturing of contracted therapeutic doses, and through royalties\u2014defined as a portion of revenues obtained by our partners from sales of Bioceltix-developed products.<\/p><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Strategic Goals<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The strategic goal of Bioceltix S.A. is to bring to the market veterinary medicinal products (drugs) for companion animals (dogs and horses, and eventually cats) that contain mesenchymal stem cells as the active pharmaceutical ingredient and are manufactured in our own facility that meets cGMP pharmaceutical standards.<\/p>

Our products will be intended to treat the most common autoimmune and inflammatory diseases, such as osteoarthritis in dogs, arthritis in horses, and atopic dermatitis in dogs.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t
Read more <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We are simultaneously developing several medicinal product candidates. Our most advanced candidate is BCX-CM-J, designed for the treatment of osteoarthritis in dogs. We are also developing BCX-CM-AD for atopic dermatitis in dogs, and BCX-EM for arthritis in horses. In our pipeline, there is also an R&D-stage project focused on developing a cell-free biological drug for the treatment of atopic dermatitis in dogs (BCX-CM-Sec).<\/p>

The development schedule for BCX-CM-J includes marketing authorisation with the European Medicines Agency<\/p>

In September 2025, we raised 52 million PLN through a public offering. The funds are being used to finance the development of a new large scale production facility .<\/p>

We have also secured approximately 35 million PLN in funding from six targeted projects co-financed by the European Regional Development Fund and the European Funds for a Modern Economy. Independently, we are planning to apply for targeted projects and EU funding.<\/p>

Authorization of medicinal products based on stem cells will follow the centralized procedure via the European Medicines Agency (EMA). The final decision to authorize a medicine for market entry under this procedure is made by the European Commission, based on EMA\u2019s recommendations.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Business Profile Go back to Investor Relations Industry Company Overview Business profile and strategic goals Industry 320 000 Number of Veterinarians in the EU and USA 28 bln USD Global expenditure on Companion Animal Healthcare in 2025 14 bln USD Veterinary biologics market in 2025 Bioceltix operates in the companion animal healthcare market which is […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":5934,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5949","page","type-page","status-publish","hentry"],"yoast_head":"\nBusiness Profile - Bioceltix<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Business Profile - Bioceltix\" \/>\n<meta property=\"og:description\" content=\"Business Profile Go back to Investor Relations Industry Company Overview Business profile and strategic goals Industry 320 000 Number of Veterinarians in the EU and USA 28 bln USD Global expenditure on Companion Animal Healthcare in 2025 14 bln USD Veterinary biologics market in 2025 Bioceltix operates in the companion animal healthcare market which is […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/\" \/>\n<meta property=\"og:site_name\" content=\"Bioceltix\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T16:12:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png\" \/>\n\t<meta property=\"og:image:width\" content=\"240\" \/>\n\t<meta property=\"og:image:height\" content=\"241\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/\",\"url\":\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/\",\"name\":\"Business Profile - Bioceltix\",\"isPartOf\":{\"@id\":\"https:\/\/bioceltix.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png\",\"datePublished\":\"2025-06-09T15:20:56+00:00\",\"dateModified\":\"2026-03-24T16:12:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#primaryimage\",\"url\":\"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png\",\"contentUrl\":\"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Strona g\u0142\u00f3wna\",\"item\":\"https:\/\/bioceltix.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Relations\",\"item\":\"https:\/\/bioceltix.com\/ir\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Business Profile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bioceltix.com\/#website\",\"url\":\"https:\/\/bioceltix.com\/\",\"name\":\"Bioceltix\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/bioceltix.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bioceltix.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/bioceltix.com\/#organization\",\"name\":\"Bioceltix\",\"url\":\"https:\/\/bioceltix.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bioceltix.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png\",\"contentUrl\":\"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png\",\"width\":274,\"height\":73,\"caption\":\"Bioceltix\"},\"image\":{\"@id\":\"https:\/\/bioceltix.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Business Profile - Bioceltix","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/","og_locale":"en_US","og_type":"article","og_title":"Business Profile - Bioceltix","og_description":"Business Profile Go back to Investor Relations Industry Company Overview Business profile and strategic goals Industry 320 000 Number of Veterinarians in the EU and USA 28 bln USD Global expenditure on Companion Animal Healthcare in 2025 14 bln USD Veterinary biologics market in 2025 Bioceltix operates in the companion animal healthcare market which is […]","og_url":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/","og_site_name":"Bioceltix","article_modified_time":"2026-03-24T16:12:08+00:00","og_image":[{"width":240,"height":241,"url":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/","url":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/","name":"Business Profile - Bioceltix","isPartOf":{"@id":"https:\/\/bioceltix.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#primaryimage"},"image":{"@id":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#primaryimage"},"thumbnailUrl":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png","datePublished":"2025-06-09T15:20:56+00:00","dateModified":"2026-03-24T16:12:08+00:00","breadcrumb":{"@id":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#primaryimage","url":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png","contentUrl":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/06\/multidyscyplinarny_zespol.png"},{"@type":"BreadcrumbList","@id":"https:\/\/bioceltix.com\/en\/investor-relations\/business-profile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Strona g\u0142\u00f3wna","item":"https:\/\/bioceltix.com\/en\/"},{"@type":"ListItem","position":2,"name":"Investor Relations","item":"https:\/\/bioceltix.com\/ir\/"},{"@type":"ListItem","position":3,"name":"Business Profile"}]},{"@type":"WebSite","@id":"https:\/\/bioceltix.com\/#website","url":"https:\/\/bioceltix.com\/","name":"Bioceltix","description":"","publisher":{"@id":"https:\/\/bioceltix.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bioceltix.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/bioceltix.com\/#organization","name":"Bioceltix","url":"https:\/\/bioceltix.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bioceltix.com\/#\/schema\/logo\/image\/","url":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png","contentUrl":"https:\/\/bioceltix.com\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png","width":274,"height":73,"caption":"Bioceltix"},"image":{"@id":"https:\/\/bioceltix.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/pages\/5949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/comments?post=5949"}],"version-history":[{"count":10,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/pages\/5949\/revisions"}],"predecessor-version":[{"id":8325,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/pages\/5949\/revisions\/8325"}],"up":[{"embeddable":true,"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/pages\/5934"}],"wp:attachment":[{"href":"https:\/\/bioceltix.com\/en\/wp-json\/wp\/v2\/media?parent=5949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}